Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Inclusion Criteria

• •Patients with relapsed or primary refractory AML (as defined in World Health Organization \[WHO\] criteria) with ≥5% bone marrow blasts
• •Patients with CD123+ blast cells (verified by flow cytometry)
• •Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1
• •Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
• •(Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
• •Other criteria may apply